Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Rhea-AI Summary
Zevra Therapeutics (NasdaqGS: ZVRA) reported publication of four-year real-world data from the U.S. Early Access Program evaluating MIPLYFFA (arimoclomol) in Niemann-Pick disease type C (NPC) in Molecular Genetics and Metabolism. The longitudinal study followed 109 participants across 14 U.S. sites, including 53 adults, with mean arimoclomol exposure of 820 days.
Disease severity, measured by the 5-domain and rescored 4-domain NPC Clinical Severity Scales, remained relatively stable over time, and safety findings were consistent with MIPLYFFA’s established profile. The data add to more than five years of global clinical experience in over 270 NPC patients.
Positive
- 109 NPC patients followed up to 4 years in U.S. Early Access Program
- Mean 820 days of arimoclomol exposure in routine clinical practice
- Mean NPC Clinical Severity Scale scores remained relatively stable over 4 years
- Safety observations were consistent with established arimoclomol safety and tolerability
- MIPLYFFA pivotal Phase 3 halted disease progression vs placebo over 1 year
- More than 5 years of experience in over 270 NPC patients worldwide
Negative
- Hypersensitivity reactions (urticaria and angioedema) reported in up to 6% of patients in Trial 1
- Mean serum creatinine increases of 10%–20% from baseline observed across clinical trials
- Embryofetal toxicity and potential fertility impairment based on animal studies
- Adverse reactions led to withdrawal in 6% of MIPLYFFA-treated patients in Trial 1
News Market Reaction – ZVRA
In the Aug 3 session, ZVRA gained 5.73%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 24 | Regulatory setback | Negative | -23.9% | EMA committee adopted a negative opinion on arimoclomol marketing authorization application |
| Jul 22 | Results call scheduling | Neutral | -2.5% | Company scheduled release of second-quarter 2026 corporate and financial results |
| Jun 23 | Pediatric clinical data | Positive | +2.8% | Infant substudy reported tolerability and pharmacokinetics consistent with older pediatric groups |
| Jun 11 | Leadership transition | Negative | -3.9% | Chief Medical Officer announced departure and planned consulting transition |
| Jun 08 | Patent listing | Positive | +13.9% | Company submitted MIPLYFFA patent for FDA Orange Book listing |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent price reactions were mostly aligned with the apparent direction of the company announcements, with one notable divergence.
Key Terms
Niemann-Pick disease type C medical
NPC Clinical Severity Scale medical
Expanded Access Programs regulatory
Marketing Authorization Application regulatory
Orphan Medicinal Product designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the publication of “Long-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Outcomes from the US Early Access Program over a 4-year period” in Molecular Genetics and Metabolism.
The longitudinal study evaluated arimoclomol in a broad US NPC population spanning a wide range of ages and disease severity, generating up to four years of follow-up data from routine clinical practice. The study includes the first published real-world data evaluating arimoclomol in adults with NPC, a historically understudied population.
"Longitudinal real-world studies can provide valuable insights that complement findings from clinical trials, particularly in ultra-rare diseases such as NPC," said Elizabeth Berry-Kravis, MD, Rush University Medical Center and lead author of the study. "Continued careful follow-up of patients over time with consistent measures that have been shown to track disease well helps advance our understanding of disease progression, clinical outcomes, and the challenges of managing NPC in everyday practice."
The US Early Access Program (EAP) included 109 participants enrolled across 14 U.S. sites, including 53 adults (
About MIPLYFFA® (arimoclomol)
MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC). Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. MIPLYFFA has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. In the pivotal phase 3 trial, MIPLYFFA halted disease progression compared to placebo over the one-year duration of the trial when measured by the only validated disease progression measurement tool, the NPC Clinical Severity Scale. MIPLYFFA has also received Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. The extensive data generated for MIPLYFFA has shown long-term, meaningful clinical outcomes with more than 5 years of patient experience across more than 270 NPC patients worldwide through a Phase 2/3 clinical trial, Open-Label Extension (OLE) study, Expanded Access Programs (EAP), and a pediatric sub-study, which is the most expansive clinical development program in NPC to date. Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C.
INDICATIONS AND USAGE
MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.
IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions: Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1: two patients reported both urticaria and angioedema (
Embryofetal Toxicity: MIPLYFFA may cause embryofetal harm when administered during pregnancy based on findings from animal reproduction studies. Advise pregnant females of the potential risk to the fetus and consider pregnancy planning and prevention for females of reproductive potential.
Increased Creatinine without Affecting Glomerular Function: Across clinical trials of MIPLYFFA, mean increases in serum creatinine of
During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function. Increases in creatinine reversed upon MIPLYFFA discontinuation.
The most common adverse reactions in Trial 1 (≥
Three (
To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. toll-free at 1-844-600-2237 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interaction(s): Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates. When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.
Use in Females and Males of Reproductive Potential: Based on animal findings, MIPLYFFA may impair fertility and may increase post-implantation loss and reduce maternal, placental, and fetal weights.
Renal Impairment: The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥15 mL/minute to <50 mL/minute is lower than the recommended dosage (less frequent dosing) in patients with normal renal function.
MIPLYFFA capsules for oral use are available in the following strengths: 47 mg, 62 mg, 93 mg, and 124 mg.
For more information, please see the full Prescribing Information, including Instructions for Use
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the potential use of arimoclomol in infants with NPC. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
